Combination Therapy for CLL Using Autophagy Modulators and CDK Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic lymphocytic leukemia (CLL) are not curative and often lead to relapse, with limited predictive methods for therapeutic response based on cytogenetic abnormalities, necessitating the development of personalized treatment approaches.
Innovation Solution
A combination therapy involving autophagy modulating agents and cyclin-dependent kinase (CDK) inhibitors is administered to enhance cytotoxicity, potentially reduce toxic side effects, and target resistance mechanisms in CLL cells, including the use of chloroquine to block autophagy and ATG4, Vps34/Beclin1/Barkor complex interference.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent therapy (CDK inhibitor alone) is used, then treatment simplicity is maintained, but therapeutic efficacy and cytotoxicity are insufficient
Solution Approach 1:
The patent combines a CDK inhibitor with an autophagy modulating agent in a single combination therapy formulation. This merging of two agents with different mechanisms of action (CDK inhibition and autophagy modulation) creates a synergistic effect that enhances cytotoxicity against CLL cells compared to CDK inhibitor alone, while maintaining manageable treatment complexity through coordinated administration protocols
2Reliability
If CDK inhibitor is administered at standard dose, then treatment protocol simplicity is maintained, but cytotoxicity and therapeutic effect are limited
Solution Approach 1:
The patent modifies the therapeutic parameters by adjusting the dosage and timing of CDK inhibitor administration in conjunction with autophagy modulating agent. The combination therapy allows for optimized dosing regimens where the CDK inhibitor can be administered at doses that achieve enhanced cytotoxicity when synergized with the autophagy modulator, rather than using standard single-agent dosing
3Reliability
If autophagy is blocked alone, then resistance mechanism is targeted, but cytotoxicity enhancement is limited
Solution Approach 1:
The patent merges the action of a CDK inhibitor with autophagy blocking agents (such as chloroquine or bafilomycin). This combination simultaneously targets multiple survival pathways in CLL cells: CDK inhibition disrupts cell cycle progression while autophagy blocking prevents the cells from utilizing autophagy as a survival mechanism, thereby synergistically enhancing cytotoxicity and overcoming resistance
4Reliability
If combination therapy is used, then cytotoxicity and therapeutic outcomes are enhanced, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent incorporates feedback mechanisms through monitoring of cytogenetic abnormalities and therapeutic response markers. By assessing patient response to the combination therapy and adjusting dosing or timing parameters based on observed outcomes, the treatment protocol maintains simplicity in execution while achieving enhanced therapeutic outcomes through data-driven optimization
Data Source
AI summary
A method of (a) treating a lymphoproliferative disease in a subject in need thereof; (b) slowing the progression of lymphoproliferative disease in a subject who has been diagnosed with a lymphoproliferative disease; or (c) preventing or delaying development of a lymphoproliferative disease in a subject who is at risk of developing a lymphoproliferative disease. The method generally comprises administering to the individual an effective amount of a combination therapy comprising: i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof; and ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof, wherein the i) agent and the ii) agents are administered in amounts sufficient to enhance the cytotoxicity of the combination relative to the CDK inhibitor agent treatment alone.